Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Elranatamab-bcmm |
Synonyms | |
Therapy Description |
Elrexfio (elranatamab-bcmm) is a bispecific antibody that binds to both TNFRSF17 (BCMA) and CD3, thereby crosslinking BCMA-expressing tumor cells and cytotoxic T-lymphocytes, potentially resulting in increased immune response against BCMA-expressing tumor cells (J Clin Oncol 39, no. 15_suppl (May 20, 2020) 8006-8006). Elrexfio (elranatamab-bcmm) is FDA -approved for use in patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (FDA.gov). |